Literature DB >> 27504888

Epidemiology of Parkinson's Disease: A Population-Based Study in Primary Care in Italy.

Elisabetta Pupillo1, Claudio Cricelli, Francesco Mazzoleni, Iacopo Cricelli, Alessandro Pasqua, Serena Pecchioli, Francesco Lapi, Ettore Beghi.   

Abstract

BACKGROUND: There are no studies on prevalence, incidence and comorbidities of Parkinson's disease (PD) in the Italian population.
METHODS: The database of 700 Italian general practitioners (population, 923,356) was investigated. All patients with International Classification of Diseases Ninth Revision - Clinical Modification (ICD-9-CM) diagnosis of PD during the period 2002-2012 were included. Parkinsonisms were excluded. Clinical conditions preceding PD were identified through ICD-9-CM codes. The Charlson Comorbidity Index was used. PD crude and standardized prevalence and annual incidence were calculated. Crude and adjusted hazard ratios were calculated for comorbidities.
RESULTS: A total of 2,204 patients (1,140 men, 1,064 women, age 22-95 years) were included. The crude prevalence of PD was 239/100,000. Prevalence increased exponentially with age. Standardized prevalence was 233 (95% CI 232-235). One hundred ninety-four patients were newly diagnosed, giving a crude incidence of 22/100,000 and a standardized incidence of 23.1/100,000 (95% CI 22.9-23.2). Incidence increased steadily until age 75-84 years and then decreased. Older age, cardiovascular and gastrointestinal disorders, diabetes, and restless-legs syndrome were associated with increased PD risk and smoking and hypersomnia with decreased PD risk. The Charlson Comorbidity Index was associated with PD risk with a documented gradient.
CONCLUSIONS: Prevalence and incidence of PD in Italy are in line with studies with the highest case ascertainment. PD risk varies with the number and type of comorbidities.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27504888     DOI: 10.1159/000448402

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  6 in total

1.  Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case-Control Study in South Korea.

Authors:  Hae-Young Park; Ji-Won Park; Hyun Soon Sohn; Jin-Won Kwon
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

2.  The path linking excessive daytime sleepiness and activity of daily living in Parkinson's disease: the longitudinal mediation effect of autonomic dysfunction.

Authors:  Ying Huang; Sidan Du; Durong Chen; Yao Qin; Jing Cui; Hongjuan Han; Xiaoyan Ge; Wenlin Bai; Xinnan Zhang; Hongmei Yu
Journal:  Neurol Sci       Date:  2022-04-30       Impact factor: 3.830

3.  The SPID-GBA study: Sex distribution, Penetrance, Incidence, and Dementia in GBA-PD.

Authors:  Letizia Straniero; Rosanna Asselta; Salvatore Bonvegna; Valeria Rimoldi; Giada Melistaccio; Giulia Soldà; Massimo Aureli; Matteo Della Porta; Ugo Lucca; Alessio Di Fonzo; Anna Zecchinelli; Gianni Pezzoli; Roberto Cilia; Stefano Duga
Journal:  Neurol Genet       Date:  2020-10-20

4.  Case-control study of hypertension and Parkinson's disease.

Authors:  Yuen-Fann Ng; Ebonne Ng; Ee-Wei Lim; Kumar M Prakash; Louis C S Tan; Eng-King Tan
Journal:  NPJ Parkinsons Dis       Date:  2021-07-21

5.  Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?

Authors:  Sebastian Heinzel; Daniela Berg; Sebastian Binder; Georg Ebersbach; Lennart Hickstein; Heinz Herbst; Michael Lorrain; Ingmar Wellach; Walter Maetzler; Gudula Petersen; Niklas Schmedt; Jens Volkmann; Dirk Woitalla; Volker Amelung
Journal:  Front Neurol       Date:  2018-06-29       Impact factor: 4.003

6.  Prevalence of Parkinson Disease in Italy: a systematic review and meta-analysis.

Authors:  Matteo Riccò; Luigi Vezzosi; Federica Balzarini; Giovanni Gualerzi; Silvia Ranzieri; Carlo Signorelli; Maria Eugenia Colucci; Nicola Luigi Bragazzi
Journal:  Acta Biomed       Date:  2020-09-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.